Berkeley Lights has released its TechAccess Subscription model to enable broader customer access to their single-cell screening technology. The new offering brings requested volume and throughput flexibility to customers who want to access the company’s cell line development and antibody discovery workflows.
The all-inclusive subscription provides customers with a comprehensive suite of products, including a Beacon system, software, consumables, service, support, and commercial use rights. Each TechAccess subscription has a renewable one-year term and provides customers with the capacity they need and the financial benefits of no up-front capital expense. The offering also provides customers with innovation insurance, providing access to Berkeley Lights’ latest technology features and capabilities.
Berkeley Lights has already started signing subscription-based access agreements with customers doing cell line development as well as antibody discovery and expects many more to come.
“Our customers have been requesting tailored access to our technology and the TechAccess Subscription model fits their specific needs,” said John Proctor, the Senior Vice President of Antibody Therapeutics at Berkeley Lights. “Since the release, we have seen a positive customer response to this program, which we believe will broaden our served available market and accelerate the adoption of Berkley Lights technology.”
Read an exclusive DDW interview with John Proctor here.
